172@29@16@16!~!172@29@0@53!~!|commonstore|commonfiles|moneycontrol_header.php?cid=0&s_cid=0&radar_off=0&is_revamped_header=0&is_responsive=1&sec=PNC_ANNOUNCEMENT&priceinter=1&frommc=1!~!www|moneycontrol|com!~!|commonstore|commonfiles|moneycontrol_header.php!~!is_mobile=false
Moneycontrol
SENSEX NIFTY
you are here:

Panacea Biotec Ltd.

BSE: 531349 | NSE: PANACEABIO |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE922B01023 | SECTOR: Pharmaceuticals

BSE Live

Oct 20, 16:00
180.75 -3.80 (-2.06%)
Volume
AVERAGE VOLUME
5-Day
8,353
10-Day
8,436
30-Day
21,393
4,788
  • Prev. Close

    184.55

  • Open Price

    178.65

  • Bid Price (Qty.)

    180.75 (19)

  • Offer Price (Qty.)

    183.50 (51)

NSE Live

Oct 20, 15:58
181.55 -1.80 (-0.98%)
Volume
AVERAGE VOLUME
5-Day
70,051
10-Day
80,670
30-Day
231,964
26,414
  • Prev. Close

    183.35

  • Open Price

    184.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    181.55 (75)

ANNOUNCEMENTS ON Panacea Biotec

  • Oct 19, 2020 18:05 Source: BSE

    Panacea Biotec - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Half-Year Ended September 30, 2020

    Pursuant to the provisions of Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith the certified copy of certificate from M/s. R & D, Company Secretaries, for the half-year ended September 30, 2020, confirming that all the transfers of shares have been completed within the stipulated time. This is for your kind information and record please.

  • Oct 16, 2020 18:10 Source: BSE

    Panacea Biotec - Shareholding for the Period Ended September 30, 2020

    Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here

  • Oct 08, 2020 14:51 Source: BSE

    Panacea Biotec - Announcement under Regulation 30 (LODR)-Resignation of Director

    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, we would like to inform you that Mrs. Sunanda Jain and Mr. Sumit Jain, Whole-time Directors of the Company, have resigned from the Board of Directors of the Company and the said resignations have become effective from the close of business hours of 7th October, 2020. You are requested to take the above information on record.

  • Oct 08, 2020 14:38 Source: NSE

    Panacea Biotec Limited

    Panacea Biotec Limited has informed the Exchange regarding ''Disclosure under Regulation 30 read with Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Non exercise of option to convert the Warrants into Equity Shares.''.

  • Oct 08, 2020 14:32 Source: BSE

    Panacea Biotec - Disclosure Under Regulation 30 Read With Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Non Exercise Of Option To Convert The Warrants Into Equity Shares

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that since the Warrant Holders did not exercise the conversion option within the aforesaid period, the Warrants stand cancelled / lapsed and the upfront amount of Rs.31,99,99,995/- (equivalent to 25% of total consideration) as received by the Company from the Warrant Holders, towards allotment of the said Warrants stands forfeited in accordance with the terms of the said Warrants and as per the provisions of Regulation 169(3) of Chapter V of SEBI ICDR Regulations

  • Oct 07, 2020 17:14 Source: BSE

    Panacea Biotec - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For The Half-Year Ended On September 30, 2020

    Pursuant to the provisions of Regulation 7(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we are enclosing herewith the certificate duly signed by Skyline Financial Services Pvt. Ltd., Share Transfer Agent and Company Secretary of Panacea Biotec Ltd. for the half year ended on September 30, 2020 in compliance of Regulation 7(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

  • Oct 07, 2020 17:11 Source: BSE

    Panacea Biotec - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, the details of Shares dematerialized during September, 2020 are enclosed herewith

  • Oct 06, 2020 16:57 Source: BSE

    Panacea Biotec - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    We would like to inform you that pursuant to the Scheme, the Resulting Company in its Board Meeting held on October 06, 2020 has issued and allotted 6,12,50,746 Equity Shares of Re.1 each and 1,63,000 0.5% cumulative non-convertible and non-participating redeemable preference shares of Rs.10/- each to the equity and preference shareholders of the Company, respectively, whose names appeared in the register of members / record of the depositories as a beneficial owner as on the Record Date i.e. September 22, 2020. The new Equity Shares issued & allotted by Resulting Company to the shareholders of the Demerged Company in accordance with the Scheme shall be listed and/or admitted to trading on the BSE Limited and National Stock Exchange of India Limited (NSE), subject to requisite approvals of Exchanges/SEBI.

  • Sep 30, 2020 17:23 Source: BSE

    Panacea Biotec - Closure of Trading Window

    Pursuant to the Company''''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company and Material Subsidiaries of the Company from October 01, 2020 till completion of 48 hours from the announcement to the Stock Exchanges regarding Unaudited financial results of the Company for the quarter and half year ended September 30, 2020. The date of meeting of the Board of Directors to approve the Unaudited financial results of the Company for the quarter and half year ended September 30, 2020, shall be informed in due course.

  • Sep 30, 2020 14:43 Source: BSE

    Panacea Biotec - Clarifies on news item

    With reference to news appeared in bloombergquint.com dated September 30, 2020 quoting "Panacea Biotech Ltd Baddi facility received a warning letter from the U.S. FDA .", Panacea Biotec Ltd has submitted to BSE a copy of Clarification is enclosed.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Sep 03, 2020
Remark : Quarterly Results